Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of MVA.HIVconsv in HIV-1 Seropositive Adults on HAART

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, aged 18-60 years~* Confirmed HIV-1 seropositive~* Willing and able to give written informed consent for participation in the study~* Treated continuously with a combination of 3 or more antiretroviral agents for the preceding 12 months~* Willing and able to adhere to an effective ART regimen for the duration of the study (switching from current regimen is allowed if for reasons of tolerability or toxicity)~* CD4 cell count \> 350 cells/μl at screening and at the preceding clinic visit~* Plasma viral load \< 50 copies / ml at screening and at the preceding clinic visit~* No new AIDS-defining diagnosis or progression of HIV-related disease in the preceding 6/12 months~* Haematological and biochemical laboratory parameters as follows:~  * Haemoglobin \> 10g/dl~ * Platelets \> 100,000/μl~ * ALT ≤ 2.5 x ULN~ * Creatinine ≤ 1.3 x ULN~* Serology: negative for hepatitis B surface antigen OR HbsAg positive with HBV DNA \< 1000 copies/ml; negative for hepatitis C antibodies OR confirmed clearance of HCV infection (spontaneous or following treatment); negative syphilis serology or documented adequate treatment of syphilis if positive EIA IgG or TPHA~* Available for follow up for duration of study (screening + 38 weeks) and willing to comply with the protocol requirements~* Women of child-bearing age must not be pregnant, planning a pregnancy or breast-feeding. Sexually active women must be willing to use an approved method of contraception from screening until 4 months after the third immunisation. Sexually active men in heterosexual relationships must be willing to use an approved method of contraception with their partners from screening until 4 months after the third immunisation.~Exclusion Criteria:~* Confirmed HIV-2 seropositive~* Positive pregnancy test~* Participation in another clinical trial within 12 weeks of study entry~* History of autoimmune disease other than HIV-related auto-immune disease which has resolved with ART~* History or clinical manifestations of any physical or psychiatric disorder which could impair the subject's ability to complete the study~* History of anaphylaxis or severe adverse reaction to vaccines~* History of alcohol or drug dependency which could, in the opinion of the investigators, impair the subject's ability to complete the study~* Previous immunisation with a recombinant MVA vaccine~* Immunisation with any experimental immunogens within 6 months of study entry~* Receipt of blood products or immunoglobulins within 6 months of study entry~* Treatment for cancer or lymphoproliferative disease within 1 year of study entry~* Receipt of vaccines other than Hepatitis B vaccine within 2 weeks of study entry or planned receipt within 2 weeks of vaccination~* Any other prior therapy which, in the opinion of the investigators, would make the individual unsuitable for the study or influence the results of the study~* Current or recent use (within last 3 months) of interferon or systemic corticosteroids or other immunosuppressive agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Low dose vaccinees (Type: EXPERIMENTAL): Individuals will receive three intramuscular injections of MVA.HIVconsv alone at a dose of 1x10\^8 pfu.
- High dose vaccinees (Type: EXPERIMENTAL): Individuals will receive three intramuscular injections of MVA.HIVconsv alone at a dose of 4x10\^8 pfu.
- Low dose placebo (Type: PLACEBO_COMPARATOR): Individuals will receive three intramuscular injections of low dose placebo
- High dose placebo (Type: PLACEBO_COMPARATOR): Individuals will receive three intramuscular injections of high dose placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).